OTCMKTS:TRSBF

3SBio - TRSBF Stock Forecast, Price & News

$0.80

0.00 (0.00%)

(As of 03/23/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.80
▼
$0.80
50-Day Range: $0.80
▼
$0.80
52-Week Range: $0.80
▼
$0.80

Volume: N/A
Average Volume: 63,275 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About 3SBio

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana-Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Receive TRSBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 3SBio and its competitors with MarketBeat's FREE daily newsletter.

TRSBF Stock News Headlines

March 14, 2023 | americanbankingnews.com

Short Interest in 3SBio Inc. (OTCMKTS:TRSBF) Drops By 11.1%

July 28, 2022 | markets.businessinsider.com

Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China

March 24, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 

August 26, 2021 | finance.yahoo.com

3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TRSBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 3SBio and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:TRSBF
CUSIP: N/A
CIK: N/A
Web: www.3sbio.com
Phone: 86 24 2538 6000
Fax: N/A
Employees: 5,292
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Jing Lou M.D. (Age 59)
Ph.D., Co-Founder, Exec. Chairman, CEO & Pres
Comp: $617.76k

Dr. Dongmei Su (Age 52)
Sr. VP & Exec. Director
Comp: $206.49k

Mr. Fei Wang (Age 44)
Chief Financial Officer

Ms. Lu Xia (Age 37)
Director of Investor Relations

Ms. Hui Dang (Age 50)
Director of Risk and Compliance Management

Mr. Thomas Folinsbee C.F.A. (Age 54)
CFA, Director of Corp. Devel.

Mr. Xin Ma (Age 56)
VP of the HR Department

Ms. Siu Kuen Lai FCIS (Age 46)
FCS, Company Sec.

Ms. Fei You (Age 43)
Director of the Fin. Department & Financial Controller

Mr. Junlin Wang (Age 49)
Pres of Guojian

Key Competitors

View All Competitors

TRSBF Stock - Frequently Asked Questions

How have TRSBF shares performed in 2023?: 3SBio's stock was trading at $0.80 on January 1st, 2023. Since then, TRSBF shares have increased by 0.0% and is now trading at $0.80.
View the best growth stocks for 2023 here.
Are investors shorting 3SBio?: 3SBio saw a decline in short interest in February. As of February 28th, there was short interest totaling 4,971,500 shares, a decline of 11.1% from the February 13th total of 5,590,900 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.
View 3SBio's Short Interest.
What is 3SBio's stock symbol?: 3SBio trades on the OTCMKTS under the ticker symbol "TRSBF."

How do I buy shares of 3SBio?: Shares of TRSBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is 3SBio's stock price today?: One share of TRSBF stock can currently be purchased for approximately $0.80.
How many employees does 3SBio have?: The company employs 5,292 workers across the globe.
How can I contact 3SBio?: 3SBio's mailing address is Shenyang Economy & Tech Development, Shenyang, Liaoning 110027. The official website for the company is www.3sbio.com. The company can be reached via phone at 86 24 2538 6000.

This page (OTCMKTS:TRSBF) was last updated on 3/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial